FreeGuest Editorial NCI’s Cancer Prevention-Interception Targeted Agent Discovery (CAP-IT) Program, a milestone in cancer prevention research December 21, 2022Vol.48 No.46By Margie Clapper
EditorialFree Top 25 stories of 2022 December 21, 2022Vol.48 No.46By Alexandria Carolan and Katie Goldberg
Cancer History ProjectFree The Cancer History Project’s top 25 stories of 2022 December 21, 2022Vol.48 No.46By Alexandria Carolan and Katie Goldberg
Moderna’s mRNA cancer vaccine improves survival in phase IIb melanoma study—first observation of efficacy in an RCT December 16, 2022Vol.48 No.45By Matthew Bin Han Ong
NCI BSA approves eight new, reissue concepts at BSA/NCAB joint meeting December 16, 2022Vol.48 No.45By Jacquelyn Cobb
In the Archives The National Cancer Act 20 years later: impact as seen by its architects in 1991 December 16, 2022Vol.48 No.45
Conversation with The Cancer LetterFree NCI Director Monica Bertagnolli has breast cancer“I have more motivation to get up every morning to keep doing what I do” December 14, 2022Vol.48 No.45By Paul Goldberg and Matthew Bin Han Ong
Conversation with The Cancer Letter FDA’s Singh and Rivera describe the “new normal”—and the future—in cancer pragmatic trials December 09, 2022Vol.48 No.44By Jacquelyn Cobb, Matthew Bin Han Ong and Paul Goldberg
NCI’s Bertagnolli & ARPA-H’s Wegrzyn have been plotting to make the most of their strengths and differences December 09, 2022Vol.48 No.44By Matthew Bin Han Ong
Guest Editorial PAMN: How cancer centers develop ways to communicate the value of research December 09, 2022Vol.48 No.44By Heidi Findlay
